What do I need to tell my doctor BEFORE I take Zobru Tablets?
- If you have an allergy to Zobru or any other part of this medicine (Zobru tablets).
- If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
- If you are taking any of these drugs: Astemizole, cisapride, erythromycin, olaparib, pimozide, quinidine, terfenadine, or voriconazole.
- If you are pregnant or may be pregnant. You will need to talk with your doctor about if this medicine (Zobru tablets) is right for you.
This is not a list of all drugs or health problems that interact with this medicine (Zobru tablets).
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this medicine (Zobru tablets) with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
Generic Name: Zobru Tablets (floo KON a zole)Brand Name: Diflucan
Medically reviewed by Drugs.com. Last updated on Jul 27, 2019.
Plasma zidovudine concentrations were determined on two occasions (before and following Zobru 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of Zobru. The mean ± SD increase in AUC was 20% ± 32% (range: –27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of Zobru, from 7.6 ± 3.6 to 5.7 ± 2.2.
Outcome and Management
The severity of liver injury from Zobru ranges from mild and transient enzyme elevations to clinically apparent hepatitis to acute liver failure and death. Most patients recover with stopping Zobru, but resolution may be slow requiring 3 to 4 months. Rechallenge may lead to recurrence and should be avoided. There is little information on cross reactivity of hepatic injury between Zobru and other antifungal azoles, such as ketoconazole, itraconazole, voriconazole and posaconazole, but a few reports suggest that there is little cross reactivity. Nevertheless, other antifungal azoles should be started with caution in patients who have suffered clinically apparent hepatotoxicity attributed to Zobru.